Abstract:Little is known about the engagement in hepatitis C virus (HCV) care and completion of HCV treatment in people living with human immunodeficiency virus (HIV) (PLWH) who have HCV coinfection in the Asia-Pacific region. Examining the HCV care cascade can identify barriers to the completion of HCV treatment and facilitate achievement of HCV micro-elimination in PLWH.To investigate the care cascade of incident HCV infections among PLWH in Taiwan.PLWH with incident HCV infections, defined as HCV seroconversion, were retrospectively identified by sequential anti-HCV testing of all archived blood samples at National Taiwan University Hospital between 2011 and 2018. All PLWH with incident HCV infections were followed until December 31, 2019. The care cascade of HCV examined included all incident HCV-infected patients, the percentages of anti-HCV antibodies detected by HIV-treating physicians in clinical care, plasma HCV RNA load tested, HCV RNA positivity diagnosed, referral to treatment assessment made, anti-HCV treatment initiated, and sustained virologic response achieved. Those who had HCV seroconversion during the interferon (IFN) era (2011-2016) and the direct-acting antiviral (DAA) era (2017-2018) were analyzed separately. The duration of HCV viremia-from the date of seroconversion to viral clearance by treatments or until the end of observation-and the incidence of sexually transmitted infections (STIs) during the HCV viremic period were estimated.During the study period, 287 of 3495 (8.2%) PLWH (92.3% being men who have sex with men) who were HCV-seronegative at baseline developed HCV seroconversion by retrospective testing of all archived blood samples. Of the 287 incident HCV infections, 277 (96.5%) had anti-HCV antibodies detected by HIV-treating physicians, 270 (94.1%) had plasma HCV RNA determined and 251 (87.5%) tested positive for HCV RNA. Of those with HCV viremia, 226 (78.7%) were referred to treatment assessment, 215 (74.9%) initiated anti-HCV treatment, and 202 (70.4%) achieved viral clearance. Compared with that in the IFN era, the median interval from HCV seroconversion by retrospective testing to detection of HCV seropositivity by HIV-treating physicians was significantly shorter in the DAA era {179 d [interquartile range (IQR) 87-434] 92 d (IQR 57-173); < 0.001}. The incidence rate of STIs in the DAA the IFN era was 50.5 per 100 person-years of follow-up (PYFU) and 38.5 per 100 PYFU, respectively, with an incidence rate ratio of 1.31 (95% confidence interval 0.96-1.77), while the duration of HCV viremia was 380 d (IQR 274-554) and 735 d (IQR 391-1447) ( < 0.001), respectively.While anti-HCV therapies are effective in achieving viral clearance, our study suggests more efforts are needed to expedite the linkage of PLWH diagnosed with incident HCV infections to HCV treatment.

Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)

Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019-21)

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach

A People-centered Decentralized Outreach Model Toward HCV Micro-elimination in hyperendemic areas: COMPACT Study in SARS Co-V2 pandemic

Quality Control Measures for Lowering the Seroconversion Rate of Hemodialysis Patients with Hepatitis B or C Virus.

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan

Dual strategy involving hospital-based study and community-based screening to eliminate hepatitis C in remote areas

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

Establishment and Development of National Community-Based Collaborative Innovation Demonstration Areas to Achieve the Control Target of Hepatitis B in China

Multi-disciplinary cooperation for the micro-elimination of hepatitis C in China: a hospital-based experience

Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

OP-3 HCV MICROELIMINATION PROGRAM IN HEMODIALYSIS PATIENTS: SUCCESS OF A MULTI-STAKEHOLDER PARTNERSHIP BASED ON A NATIONAL ERADICATION STRATEGY

Universal Screening and Treatment Towards the Elimination of Chronic Hepatitis C in China: an Economic Evaluation

Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives

A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China

Hepatitis C Virus Cure with Direct-Acting Antivirals: Clinical, Economic, Societal and Patient Value for China

Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan